307 results about "Viral Myocarditis" patented technology

The invention relates to a decoction for treating viral myocarditis, which adopts traditional Chinese herbal medicines with cheap price to serve as raw materials, and mainly adopts Chinese medical materials of astragalus mongholicus, ginseng, liriope, roasted schisandra chinensis, root of red-rooted salvia, cassia twig, fried radix paeoniae rubra, white poria cocos, radix glycyrrhizae preparata and the like. A preparation method is simple, and the decoction is obtained by decocting the Chinese medical materials according to the basis principle of strengthening the body resistance to eliminate pathogenic factors and reasonable matching. The decoction for treating the viral myocarditis can meet the requirement of clinical treatment and perform dialectical treatment according to condition of the body, the difference between new and old diseases and the symptom difference of the viral myocarditis, and has remarkable characteristics and advantages of being convenient to take, reasonable in prescription matching and remarkable in curative effect of the viral myocarditis.

A Chinese medicine for treating viral myocarditis is prepared from 10 Chinese-medicinal materials including astragalus root, rehmannia root, honeysuckle flower, coptis root, etc. Its preparing process and its quality control method are also disclosed.

The invention relates to a Chinese medicinal preparation and process for preparing, wherein the main raw materials include goldthread root, pinellia tuber, dried orange peel, poria cocos, licorice root, fresh ginger, bamboo shavings and immature bitter orange. The preparation can be used for treating insomnia, depression, coronary disease, gastritis, viral myocarditis and diabetes.

The invention belongs to the field of medicines and particularly relates to a new application of an iridoid glycoside compound, genipin-1-[beta]-D-gentiobioside, and a composition composed by compounding the genipin-1-[beta]-Dgentiobioside with other components as effective components for preparing antiviral drugs, antibacterial drugs, fever alleviating drugs, inflammation resistant drugs and anti-oxidizing drugs. The iridoid glycoside compound and the composition can be used for treating acute respiratory infection, flu, pneumonia, viral hepatitis type B, herpes zoster, herpes viral keratitis, viral myocarditis, Epstein-Barr virus infection, retrovirus infectious diseases and bacterial infectious diseases.

The invention discloses a traditional Chinese medicine formula for treating vital myocarditis. The traditional Chinese medicine formula comprises the following components in percentage by weight: 10g of honeysuckle, 10g of fructus forsythia, 10g of isatis root, 10g of cyrtomium fortune, 20g of astragalus mongholicus, 10g of Tuckahoe, 10g of ginseng, 15g of salvia miltiorrhiza, 10g of ligusticum wallichii, 10g of radix rehmanniae, 10g of bighead atractylodes rhizome, 15g of polygala tenuifolia, 10g of radix ophiopogonis, 15g of acorus gramineu and 10g of liquorice; in addition, 10g of folium isatidis and 10g of dandelion are added during the acute phase of vital myocarditis; and 10g of schisandra chinensis and 10g of bighead atractylodes rhizome are added during the chronic phase of vital myocarditis. The traditional Chinese medicine formula disclosed by the invention is based on the therapeutic principle of clearing away heat and toxic materials, strengthening healthy qi and consolidating superficies and activating blood circulation, is capable of effectively treating vital myocarditis, obvious in effect in clinical practice and worth of wide popularization and application, and has no toxic or side effect.

The invention provides a traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis. The traditional Chinese medicine preparation comprises the following components in parts by weight: 10-20 parts of radix bupleuri, 10-20 parts of cape jasmine, 10-20 parts of fructus forsythiae, 10-20 parts of radix pseudostellariae, 10-20 parts of prepared rehmannia root, 10-20 parts of cassia twig, 10-20 parts of fructus ligustri lucidi, 10-20 parts of oldenlandia diffusa, 10-20 parts of radix ophiopogonis, 10-20 parts of the root of red-rooted salvia, 10-20 parts of carthamus tinctorius, 10-20 parts of radix paeoniae alba, 10-20 parts of pseudo-ginseng, 10-20 parts of astragalus mongholicus, 10-20 parts of prepared fleece flower root, 10-20 parts of poria cocos, 10-20 parts of vegetable sponge, 10-20 parts of ligusticum wallichii, 10-20 parts of curcuma zedoary, 10-20 parts of scutellaria baicalensis, 10-20 parts of albizia julibrissin, 10-20 parts of silkworm larva, 10-20 parts of angelica sinensis, and 10-20 parts of platycladi seeds. The traditional Chinese medicine preparation disclosed by the invention is capable of rapidly in-flowing blood, directly achieving myocardium and rapidly increasing myocardial contraction force and has the main functions of detoxifying, removing stasis, clearing heat, opening the inhibited lung-energy and clearing away the heart-fire; in addition, the functions of tonifying qi and calming the mind and the functions of soothing the liver and reducing heat are combined, the functions of rapidly relieving patient conditions and saving lives of patients are achieved.

The present invention aims at providing a pharmaceutical composition for the prophylaxis or treatment, irrespective of the kind of virus, of viral myocarditis or viral diseases induced by viral myocarditis, by the treatment or prevention of the onset of cytotoxicity in various organs, and a method of the prophylaxis or treatment. The present invention also relates to a pharmaceutical composition for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which contains 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof as an active ingredient. The present invention further relates to a method for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which includes administering an effective amount of the aforementioned compound or a pharmacologically acceptable salt thereof.

The invention discloses a medicine for treating cardiocerebrovascular diseases, which is mainly prepared by the following raw materials: coenzyme Q10 (CoQ10), Vitamin E (VE) and soybean lecithin (PC). The medicine is widely used for treating coronary heart disease, cardiac failure, arrhythmia, rheumatic heart disease, viral myocarditis, blood supply deficiency, high blood pressure, and other cardiocerebrovascular diseases and periodontitis resulted from gingival atrophy and also can be used as adjuvant therapy for acute and chronic viral hepatitis and cancer, which also has the efficacies of decreasing blood lipid, lowering cholesterol, regulating internal secretion, eliminating climacteric syndrome, resisting aging, preventing senile dementia, etc. In addition, the invention also discloses a production method for preparing the medicine for treating cardiocerebrovascular diseases with semisynthetic raw material.

The present invention relates to a Chinese medicine for effectively curing viral myocarditis and cardiomyopathy with excellent therapeutic effect. It is made up by using 16 Chinese medicinal materials of antelope horn, coptis root, codonopsis root, astragalus root, flavescent sophora root and others through a certain preparation process.

The invention provides a traditional Chinese medicine preparation for treating pediatric viral myocarditis. The preparation comprises raw materials of Radix Ophiopogon, therootofred-rootedsalvia, cassia twig, alliummacrostemon, rootofcommonpeony, Schisandra chinensis, pseudo-ginseng, Astragalusmongholicus, Fructus Trichosanthis, Fructus Forsythiae, Semen Platycladi, Rhizoma Atractylodis, luffa vegetable sponge, angelica, Ligusticumwallichii, curcuma zedoary, ginger processed pinellia, the root of large-flowered skullcap, polygala root, earthworm, and Radix aucklandiae. The invention aims to prepare a medicine for treating myocarditis from selected traditional Chinese medicines. The prepared medicine not only can improve the metabolism of myocardium and myocardial nutrition, protect the heart cells and improve myocardial disease resistance, but also can directly kill virus, reduce the damage of virus on myocardium, and realize combination of antivirus and overall regulation; and the medicine can reduce deputy effects caused by long-term application of Western medicine on the human body, and is an ideal medicine for treating myocarditis. In addition, the medicine prepared by the invention contains a large amount of active ingredients, employs cheap raw materials and simple preparation method, and can be widely used in clinical practice.

The invention belongs to the field of medicaments, discloses application of lycorine, lycorine salt, lycorine hydrate, lycorine optical isomer or lycorine prodrug in preparing medicaments for treating diseases caused by human enterovirus 71 type infection, preferably treating hand-foot-and-mouth disease, herpangina, viral meningitis, viral encephalitis, flaccid paralysis, pulmonary edema and vital myocarditis. In vitro and in vivo tests prove that the lycorine can inhibit replication and lesion of enterovirus (EV) 71 in cells, has excellent function of inhibiting the EV 71 virus, and has clinical application prospect.

An orally taken Chinese medicing for treating viral myocarditis is prepared from 7 Chinese-medicinal materials including astragalus root, Chinese angelica roto, white peony root, Chuan-xiong rhizome, etc.

The invention provides a traditional Chinese medicine composition for treating viral myocarditis. The composition is prepared from daphne koreana nakai, purple flower holly leaf, liquorice, lily, evening primrose of safflower, giant knotweed rhizome, baical skullcap root, rhizome of medical angiopteris, snake slough, paniculate swallowwort root, olive, dangshen, glossy privet fruit, lagochilus lanatonodus, rhizoma corydalis and long pepper. The composition can be clinically used for treating viral myocarditis.

The present invention is the application of white flower red sage in preparing medicine and the preparation process of white flower red sage medicine. White flower red sage has danshensu content as high as 2 times that of purple flower red sage, and danshensu is the main effective component for treating cardiac and cerebral vascular diseases and other relevant diseases, and possesses the functions of promoting blood circulation to disperse blood clots, relieving pain, dredging meridian and clearing away heart fire. The white flower red sage medicine has high curative effect on various cardiac and cerebral vascular diseases, and may be also used in treating pulmonary heart disease, viral myocarditis, hypertension, etc.

The invention discloses application of long-chain non-coding RNA in regulating polarization of macrophages in viral myocarditis. The applicant found that the differential expression of lncRNA AK085865in M1/M2 macrophages is the most significant, and that the expression level of AK085865 in M2 macrophages is higher than the expression level of AK085865 in M2 macrophages. The down-regulation of AK085865 gene reduces the phenotypic expression of M2 and promotes the polarization of M1 phenotype. Meanwhile, the susceptibility of AK085865-/- gene knockout mice to CVB3-induced VM increases. In the AK085865-/- gene knockout VM model mice, M1 macrophages increase significantly while the number of M2 cells decreases. The AK085865 specifically interacts with an interleukin enhancer binding factor 2,and plays a negative regulation role in the ILF2/ILF3 complex-mediated microRNA processing pathway and promotes the polarization of M2 macrophages.

An interior-applied Chinese medicine for treating the Yin-blood deficiency type viral myocarditis is prepared from 13 Chinese-medicinal materials including red sage root, pilose asiabell root, flavescent sophora root, coptis root, etc.

The present invention discloses a viral myocarditis gene vaccine, Said vaccine is constructed by using B3 type Coxsackie virus structural protein VPI gene and pcDNA carrier together, and its exterior is covered with a biological polysaccharide. It also discloses a method for preparing said gene vaccine and the application of said gene vaccine in preparation of medicine for preventing viral myocarditis.

The invention relates to a sophoridine nanoliposome drug and the preparation method. The invention provides a sophoridine nanoliposome drug and the material and the content of the material are as follows: 350-500 compound of HSPC for injection and Vitamin E with a mass ration 9.8: 0.2; 20 to 30 compound of cholesterol and Beta-sitosterol with a mass ratio 1 to 3:1; sophoridine 10 to 25; 125 to 200 compound of dextran 40 and mannitol with a mass ratio 1: 7 to 9; 5 to 10reduced glutathione; and poloxamer F-6835-40. The invention also provides the preparation method of the sophoridine nanoliposome. The drug provided in the invention can be used to treat adenocarcinoma, inflammation, gout, progressive disease of the central nervous system, to relieve pain and treat viral myocarditis.

The invention discloses use of palchouli oil in preparation of an antiviral drug, and discloses an antiviral pharmaceutical composition, which is a drug prepared from the palchouli oil as an active ingredient and a pharmaceutically acceptable auxiliary material or an auxiliary ingredient. The palchouli oil disclosed by the invention is significant in anti-virus effect, can treat a disease caused by virus, is accurate in curative effect on vital myocarditis and pneumonia, and has strong practical application value.

The invention provides a anti-myocardial antibody four-linking diagnostic reagent kit, including the coated reaction plate packaged the same antigen atomic manpower synthetic peptide antigen with four myocardial antigens, horseradish peroxidase labeled goat anti-human IgG ELISA two-antibody, sample dilution solution, enrichment solution, color reagent A, color reagent B, negative corresponding serum, termination solution, and brochure. The reagent kit of the invention has high sensitivity and strong specificity for viral myocarditis and dilated cardiomyopathy.